Viatris in den Nachrichten
Umfassende Medikamentenportfolio-Versorgung
Tamtam hat 18 aktuelle Artikel über Viatris gefunden.
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- Harrow Closes Acquisition of Tyrvaya, a Dry Eye Disease Treatment From Viatris Inc.
- A third-quarter results call is set for 8:30 a.m. ET on Nov. 5, with Viatris executives hosting.
- Viatris’s pipeline strategy: Moving beyond generics to find new growth
- Should Value Investors Buy Viatris (VTRS) Stock?
- Harrow Closes Acquisition of Tyrvaya from Viatris
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- UBS Adjusts Price Target on Viatris to $26 From $23, Keeps Buy Rating
- Viatris to report Q3 2026 earnings on Nov 5 wit...
- UBS raises Viatris stock price target on cenerimod outlook
- Net income before discontinued operations of Viatris, Inc. – HAN:VIA
- Viatris Inc. stock falls Wednesday, underperforms market
- Return on invested capital % of Viatris, Inc. – HAN:VIA
- Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
- Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture.
- Will Japan WAKIX Approval Change Viatris (VTRS) Stock Narrative
- Is Viatris (VTRS) Cheap On Its Japan WAKIX Approval?
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Viatris?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden